Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia

J Clin Psychopharmacol. 2016 Oct;36(5):492-5. doi: 10.1097/JCP.0000000000000555.


We conducted a cross-sectional study to compare the subjective experiences and clinical effects of first-generation long-acting injectable (FGA-LAI) antipsychotics with those of risperidone long-acting injectables (RIS-LAIs) in 434 schizophrenia patients. Compared with the RIS-LAI group, the patients treated with FGA-LAIs had a significantly longer duration of illness and LAI treatment and were older. Our results suggest that patients treated with FGA-LAI have more satisfactory subjective experiences compared with patients treated with RIS-LAI and that both FGA-LAI and RIS-LAI treatments can prevent relapses and hospitalization. Additional longitudinal studies determining the long-term benefits of RIS-LAI are warranted.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / pharmacology*
  • Cross-Sectional Studies
  • Delayed-Action Preparations
  • Female
  • Humans
  • Injections
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care*
  • Patient Reported Outcome Measures
  • Risperidone / administration & dosage
  • Risperidone / pharmacology*
  • Schizophrenia / drug therapy*


  • Antipsychotic Agents
  • Delayed-Action Preparations
  • Risperidone